Pharmaceuticals

Fuan Pharmaceutical

Fuan Pharmaceutical released FY2025 Q4 earnings on April 26 After-Market (BJT), actual revenue CNY 422.92 M, actual EPS CNY -0.0568

Fuan Pharmaceutical released FY2026 Q1 earnings on April 26 After-Market (BJT), actual revenue CNY 407.49 M, actual EPS CNY 0.05

Fuan Pharmaceutical released FY2025 annual earnings on April 26 After-Market (BJT), actual revenue CNY 1.738 B, actual EPS CNY 0.06

Fuan Pharmaceutical FY2026 Q1 Earnings Release on April 27 After-Market (BJT)

Fuan Pharmaceutical to Release FY2025 Earnings on April 27 After-Market (BJT)

Fuan Pharmaceutical released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 394.87 M, actual EPS CNY 0.0408

Fuan Pharmaceutical released FY2025 9 Months Earnings on October 27 After-Market BJT, actual revenue CNY 1.315 B, actual EPS CNY 0.1405

Fuan Pharmaceutical to Release FY2025 Q3 Earnings on October 28 After-Market (BJT)

Fuan Pharmaceutical released FY2025 Q2 earnings on August 26 After-Market (BJT), actual revenue CNY 452.83 M, actual EPS CNY 0.0396

Fuan Pharmaceutical released FY2025 Semi-Annual Earnings on August 26 After-Market (BJT), with actual revenue of CNY 920.51 M and EPS of CNY 0.0999

Fuan Pharmaceutical to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

FA YAO PHARMACEUTICAL'S CSO EXPLAINS LONG-ACTING GROWTH HORMONE R&D PROJECT NATURE

Fuan Pharmaceutical's Subsidiary Tianheng Pharmaceutical Obtains Adenosylcobalamin Capsules Drug Registration Certificate

Fuan Pharmaceutical Subsidiary Obtains Certificate for Sodium Benzylpenicillin for Injection

Fu'an Pharmaceutical Plans to Actively Expand Overseas Market

Fuan Pharmaceutical Announces No Anti-Aging Drugs in R&D Projects

Fuan Pharmaceutical's First Quarter Profits Plunge

Fuan Pharmaceutical Reports 43.63% Decline in Net Profit for Q1 2025

Fuan Pharmaceutical released FY2024 earnings on April 23 After-Market (BJT), actual revenue CNY 2.391 B, actual EPS CNY 0.24

Fuan Pharmaceutical released FY2025 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 467.68 M, actual EPS CNY 0.06

300194

According to the Zhitong Finance APP, Fuan Pharmaceutical released its third-quarter report for 2025. The company's operating income for the first three quarters was 1.315 billion yuan, a year-on-year decrease of 34.08%. The net profit attributable to shareholders of the listed company was 166 million yuan, a year-on-year decrease of 44.87%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 148 million yuan, a year-on-year decrease of 47.53%. The basic earnings per share were 0.14 yuan

Zhitong

Fuan Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 166 million yuan, a decrease of 44.87%

Fuan Pharmaceutical Co., Ltd. announced the 2025 semi-annual equity distribution plan on September 15. A cash dividend of 0.2 yuan will be distributed for every 10 shares, with a total distribution amount of 23,794,247.64 yuan. The equity registration date is September 24, and the ex-dividend date is September 25. The distribution is for all registered shareholders, and the cash dividend will be credited on September 25

Fuan Pharmaceutical Announcement on the Implementation of the 2025 Half-Year Equity Distribution Plan

According to the Zhitong Finance APP, Fuan Pharmaceutical released its semi-annual report for 2025, showing an operating income of 921 million yuan, a year-on-year decrease of 35.76%. The net profit attributable to shareholders of the listed company was 113 million yuan, a year-on-year decrease of 47.74%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 104 million yuan, a year-on-year decrease of 48.84%. The basic earnings per share were 0.1 yuan

Fuan Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 113 million yuan, a decrease of 47.74%

00691

The Asian market is attracting attention as investors focus on penny stocks amid changing trade policies and monetary adjustments. Notable penny stocks include K. Wah International Holdings, China Shanshui Cement Group, and Fuan Pharmaceutical (Group), each with varying market caps and financial health ratings. K. Wah has a market cap of HK$7.79 billion but faces declining earnings. China Shanshui, with a market cap of HK$3.83 billion, has seen volatile prices and a recent net loss. Fuan Pharmaceutical, valued at CN¥5.85 billion, shows operational resilience despite negative earnings growth.

Simplywall

SHANSHUI CEMENT

Asian Market Highlights: Penny Stocks To Watch In August 2025

The chemical pharmaceutical sector saw a short-term surge, with Fuan Pharmaceutical rising over 10%. Yuyuan Pharmaceutical, Weier Pharmaceutical, Dezhan Health, Jingxin Pharmaceutical, and Zhendong Pharmaceutical also followed suit

The chemical pharmaceutical sector sees a short-term surge, with Fuan Pharmaceutical rising over 10%

000990

300138

Rhein Biotech hit the daily limit, Fuan Pharmaceutical and CCGB rose over 5%, while Yongji Co., Ltd., Dezhan Health, Chengzhi, and Kang En Bei also followed suit

Chengzhi

CCGB

Industrial hemp concept stocks opened strong, with Rhine Biotech hitting the daily limit

According to the Zhitong Finance APP, Fuan Pharmaceutical announced that its wholly-owned subsidiary Fuan Pharmaceutical Group Yantai Zhichu Pharmaceutical Co., Ltd. (referred to as "Zhichu Pharmaceutical") recently received a drug registration certificate issued by the National Medical Products Administration, for the drug named Injection Ademetionine. Injection Ademetionine is suitable for pre-cirrhosis and intrahepatic cholestasis caused by cirrhosis; it is also suitable for intrahepatic cholestasis during pregnancy

Fuan Pharmaceutical: The registration of injectable adenosine dimethylsulfonate has been completed

600196

02196

002422

CITIC Securities released a research report indicating that the trend of policy optimization such as centralized procurement is strengthening, and it is expected that the pharmaceutical sector will steadily rise in the second half of the year. Since 2025, the government has repeatedly proposed policies to optimize drug centralized procurement and support innovative drugs, and the commercial insurance catalog for innovative drugs is about to be released, creating a favorable pharmaceutical policy environment. It is recommended to pay attention to layouts in areas such as innovation-driven, internationalization, self-control, and reforms in out-of-hospital marketing models

FOSUN PHARMA

KELUN PHARMA

CITIC Securities: The trend of policy optimization such as centralized procurement is strengthening in certainty, and the pharmaceutical sector is expected to steadily rise in the second half of the year

According to the Zhitong Finance APP, Fuan Pharmaceutical announced that its wholly-owned subsidiary Fuan Pharmaceutical Group Yantai Zhichu Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhichu Pharmaceutical") recently received a drug registration certificate issued by the National Medical Products Administration, involving the product: Alpha-Lipoic Acid Tablets. The indication for Alpha-Lipoic Acid Tablets is: used for sensory abnormalities caused by diabetic peripheral neuropathy

Fuan Pharmaceutical's subsidiary has received the drug registration certificate for Alpha-Lipoic Acid Tablets

Fuan Pharmaceutical expects a net profit attributable to the parent company of 100 million to 130 million yuan in the first half of 2025, a year-on-year decrease of 39.95% to 53.81%. The net profit after deducting non-recurring gains and losses is expected to be 91 million to 121 million yuan, a year-on-year decrease of 40.50% to 55.25%. The company stated that the implementation of centralized procurement policies has led to a significant decline in the sales prices of major products, resulting in reduced operating income and pressure on profit margins

Fuan Pharmaceutical issued a profit warning, expecting a net profit attributable to the parent company of 100 million to 130 million yuan in the first half of the year, a year-on-year decrease of 39.95% to 53.81%

Fuan Pharmaceutical(300194.SZ)